Omics Technology facility
Omics Technology facility
批准号:
10703083
负责人:
Liang Cao
金额:
$82.28万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
ATAC-seqAlgorithmsAntibodiesAreaBioinformaticsBiologicalBiological AssayBiologyCCRCellsChIP-seqClassificationClinicalCommunitiesComputational BiologyContractorCooperative Research and Development AgreementCustomDNADNA analysisDNA sequencingDataData AnalysesDetectionDevelopmentEnhancersEpigenetic ProcessFoundationsFundingGene RearrangementGenesGeneticGenomeGoalsImmunogenomicsIndustrializationIntentionInternetLaboratoriesLeftMachine LearningMalignant NeoplasmsMediatingMethodsMicrococcal NucleaseMolecular ProfilingMolecular TargetMutation DetectionOncogenesPositioning AttributeProteomicsProtocols documentationRNAResearchResearch PersonnelResourcesSequence AnalysisStructureT-LymphocyteTechnologyTrainingTumor AntigensUnited States National Institutes of HealthValidationWorkassay developmentbasebiomarker developmentclinical biomarkersconvolutional neural networkepigenetic regulationexome sequencinggenome sequencinginnovationmass spectrometric imagingmembernew technologynext generation sequencingoperationrecruitresponsescreeningsingle-cell RNA sequencingtargeted sequencingtechnology developmenttooltranscriptome sequencingtumorwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
As the project was started in this fiscal year, the main effort was focused on the establishment of operation and in the development of core technologies. A. Team formation: 1. Web lab: Two additional members were transferred to us in April of FY22 from the previous Molecular Profile/Clinomics Core, one of which had since left NCI in June 22. We'll fill in this vacate position in FY23. 2. IT team: Two members were recruited to the IT team via the NCI Frederick contractor. This IT team is currently helping to establish the pipelines for Next Generation Sequencing (NGS) data analysis. B. Core technology development. We are mainly focused on establishing NGS-based technologies for discovery cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
-
批准号:8763754
-
项目类别:
-
资助金额:$26.85万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
-
批准号:9153812
-
项目类别:
-
资助金额:$1.61万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Omics Technology facility
-
批准号:10926658
-
项目类别:
-
资助金额:$94.53万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Biomarker Investigations for Clinical Trials
-
批准号:10703033
-
项目类别:
-
资助金额:$82.28万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
-
批准号:8350134
-
项目类别:
-
资助金额:$19.83万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
-
批准号:8554103
-
项目类别:
-
资助金额:$28.52万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations
-
批准号:8158346
-
项目类别:
-
资助金额:$19.1万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
-
批准号:8157684
-
项目类别:
-
资助金额:$25.47万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
-
批准号:9344164
-
项目类别:
-
资助金额:$8.42万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations
-
批准号:7969993
-
项目类别:
-
资助金额:$18.14万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Biomarker Investigations for Clinical Trials
-
批准号:10926608
-
项目类别:
-
资助金额:$94.53万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
-
批准号:8349379
-
项目类别:
-
资助金额:$13.22万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Biomarker Investigations for Clinical Trials
-
批准号:9556814
-
项目类别:
-
资助金额:$82.98万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Predictive Biomarkers and Mechanism of Action for Anti-IGF1R Agents for Cancer
-
批准号:7733446
-
项目类别:
-
资助金额:$31.69万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Omics Technology facility
-
批准号:10487274
-
项目类别:
-
资助金额:$17.01万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Biomarker Investigations for Clinical Trials
-
批准号:10262737
-
项目类别:
-
资助金额:$102.59万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Predictive Biomarkers and Mechanism of Action for Anti-IGF1R Agents for Cancer
-
批准号:7970018
-
项目类别:
-
资助金额:$18.14万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Molecular Pathogenic Mechanism of Rhabdomyosarcoma
-
批准号:8553029
-
项目类别:
-
资助金额:$7.13万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Design, Develop, Validate, and Implement Biomarkers for Clinical Investigations
-
批准号:7733385
-
项目类别:
-
资助金额:$21.13万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
Preclinical Development of Novel Targeted Therapeutics Against Pediatric Sarcoma
-
批准号:9154315
-
项目类别:
-
资助金额:$14.5万
-
财政年份:--
-
负责人:Liang Cao
-
依托单位:
海外基金